Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Co-engaging CD47 and CD19 with a bispecific antibody abrogates B-cell receptor/CD19 association leading to impaired B-cell proliferation.

Hatterer E, Barba L, Noraz N, Daubeuf B, Aubry-Lachainaye JP, von der Weid B, Richard F, Kosco-Vilbois M, Ferlin W, Shang L, Buatois V.

MAbs. 2019 Feb/Mar;11(2):322-334. doi: 10.1080/19420862.2018.1558698. Epub 2019 Jan 31.

2.

Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia.

Buatois V, Johnson Z, Salgado-Pires S, Papaioannou A, Hatterer E, Chauchet X, Richard F, Barba L, Daubeuf B, Cons L, Broyer L, D'Asaro M, Matthes T, LeGallou S, Fest T, Tarte K, Clarke Hinojosa RK, Genescà Ferrer E, Ribera JM, Dey A, Bailey K, Fielding AK, Eissenberg L, Ritchey J, Rettig M, DiPersio JF, Kosco-Vilbois MH, Masternak K, Fischer N, Shang L, Ferlin WG.

Mol Cancer Ther. 2018 Aug;17(8):1739-1751. doi: 10.1158/1535-7163.MCT-17-1095. Epub 2018 May 9.

3.

Tumor-Directed Blockade of CD47 with Bispecific Antibodies Induces Adaptive Antitumor Immunity.

Dheilly E, Majocchi S, Moine V, Didelot G, Broyer L, Calloud S, Malinge P, Chatel L, Ferlin WG, Kosco-Vilbois MH, Fischer N, Masternak K.

Antibodies (Basel). 2018 Jan 3;7(1). pii: E3. doi: 10.3390/antib7010003.

4.

Dual display: phage selection driven by co-engagement of two targets by two different antibody fragments.

Fagète S, Botas-Perez L, Rossito-Borlat I, Adea K, Gueneau F, Ravn U, Rousseau F, Kosco-Vilbois M, Fischer N, Hartley O.

Protein Eng Des Sel. 2017 Sep 1;30(9):575-582. doi: 10.1093/protein/gzx021.

PMID:
28444391
5.

Magnetic sorting of membrane associated IgG for phenotype-based selection of stable antibody producing cells.

Poitevin Y, Pontini G, Fischer N, Kosco-Vilbois M, Elson G.

J Immunol Methods. 2017 May;444:1-6. doi: 10.1016/j.jim.2017.02.004. Epub 2017 Feb 9.

PMID:
28189705
6.

Antibody Neutralization of CXCL10 in Vivo Is Dependent on Binding to Free and Not Endothelial-bound Chemokine: IMPLICATIONS FOR THE DESIGN OF A NEW GENERATION OF ANTI-CHEMOKINE THERAPEUTIC ANTIBODIES.

Bonvin P, Gueneau F, Buatois V, Charreton-Galby M, Lasch S, Messmer M, Christen U, Luster AD, Johnson Z, Ferlin W, Kosco-Vilbois M, Proudfoot A, Fischer N.

J Biol Chem. 2017 Mar 10;292(10):4185-4197. doi: 10.1074/jbc.M116.745877. Epub 2017 Jan 30.

7.

Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies.

Dheilly E, Moine V, Broyer L, Salgado-Pires S, Johnson Z, Papaioannou A, Cons L, Calloud S, Majocchi S, Nelson R, Rousseau F, Ferlin W, Kosco-Vilbois M, Fischer N, Masternak K.

Mol Ther. 2017 Feb 1;25(2):523-533. doi: 10.1016/j.ymthe.2016.11.006.

8.

Spatiotemporal expression of endogenous TLR4 ligands leads to inflammation and bone erosion in mouse collagen-induced arthritis.

Kiyeko GW, Hatterer E, Herren S, Di Ceglie I, van Lent PL, Reith W, Kosco-Vilbois M, Ferlin W, Shang L.

Eur J Immunol. 2016 Nov;46(11):2629-2638. doi: 10.1002/eji.201646453. Epub 2016 Sep 6.

9.

A specific anti-citrullinated protein antibody profile identifies a group of rheumatoid arthritis patients with a toll-like receptor 4-mediated disease.

Hatterer E, Shang L, Simonet P, Herren S, Daubeuf B, Teixeira S, Reilly J, Elson G, Nelson R, Gabay C, Sokolove J, McInnes IB, Kosco-Vilbois M, Ferlin W, Monnet E, De Min C.

Arthritis Res Ther. 2016 Oct 6;18(1):224.

10.

Use of a mouse model to identify a blood biomarker for IFNγ activity in pediatric secondary hemophagocytic lymphohistiocytosis.

Buatois V, Chatel L, Cons L, Lory S, Richard F, Guilhot F, Johnson Z, Bracaglia C, De Benedetti F, de Min C, Kosco-Vilbois MH, Ferlin WG.

Transl Res. 2017 Feb;180:37-52.e2. doi: 10.1016/j.trsl.2016.07.023. Epub 2016 Aug 4.

PMID:
27559680
11.

Blocking interferon γ reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritis.

Corbera-Bellalta M, Planas-Rigol E, Lozano E, Terrades-García N, Alba MA, Prieto-González S, García-Martínez A, Albero R, Enjuanes A, Espígol-Frigolé G, Hernández-Rodríguez J, Roux-Lombard P, Ferlin WG, Dayer JM, Kosco-Vilbois MH, Cid MC.

Ann Rheum Dis. 2016 Jun;75(6):1177-86. doi: 10.1136/annrheumdis-2015-208371. Epub 2015 Dec 23.

12.

Novel Insights into Interleukin 6 (IL-6) Cis- and Trans-signaling Pathways by Differentially Manipulating the Assembly of the IL-6 Signaling Complex.

Lacroix M, Rousseau F, Guilhot F, Malinge P, Magistrelli G, Herren S, Jones SA, Jones GW, Scheller J, Lissilaa R, Kosco-Vilbois M, Johnson Z, Buatois V, Ferlin W.

J Biol Chem. 2015 Nov 6;290(45):26943-53. doi: 10.1074/jbc.M115.682138. Epub 2015 Sep 11.

13.

Therapeutic Effects of Treatment with Anti-TLR2 and Anti-TLR4 Monoclonal Antibodies in Polymicrobial Sepsis.

Lima CX, Souza DG, Amaral FA, Fagundes CT, Rodrigues IP, Alves-Filho JC, Kosco-Vilbois M, Ferlin W, Shang L, Elson G, Teixeira MM.

PLoS One. 2015 Jul 6;10(7):e0132336. doi: 10.1371/journal.pone.0132336. eCollection 2015.

14.

Robust Antibody-Antigen Complexes Prediction Generated by Combining Sequence Analyses, Mutagenesis, In Vitro Evolution, X-ray Crystallography and In Silico Docking.

Loyau J, Didelot G, Malinge P, Ravn U, Magistrelli G, Depoisier JF, Pontini G, Poitevin Y, Kosco-Vilbois M, Fischer N, Thore S, Rousseau F.

J Mol Biol. 2015 Aug 14;427(16):2647-62. doi: 10.1016/j.jmb.2015.05.016. Epub 2015 May 24.

PMID:
26013163
15.

Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG.

Fischer N, Elson G, Magistrelli G, Dheilly E, Fouque N, Laurendon A, Gueneau F, Ravn U, Depoisier JF, Moine V, Raimondi S, Malinge P, Di Grazia L, Rousseau F, Poitevin Y, Calloud S, Cayatte PA, Alcoz M, Pontini G, Fagète S, Broyer L, Corbier M, Schrag D, Didelot G, Bosson N, Costes N, Cons L, Buatois V, Johnson Z, Ferlin W, Masternak K, Kosco-Vilbois M.

Nat Commun. 2015 Feb 12;6:6113. doi: 10.1038/ncomms7113.

16.

 De novo isolation of antibodies with pH-dependent binding properties.

Bonvin P, Venet S, Fontaine G, Ravn U, Gueneau F, Kosco-Vilbois M, Proudfoot AE, Fischer N.

MAbs. 2015;7(2):294-302. doi: 10.1080/19420862.2015.1006993.

17.

Maximizing the potency of an anti-TLR4 monoclonal antibody by exploiting proximity to Fcγ receptors.

Loyau J, Malinge P, Daubeuf B, Shang L, Elson G, Kosco-Vilbois M, Fischer N, Rousseau F.

MAbs. 2014;6(6):1621-30. doi: 10.4161/19420862.2014.975098.

18.

Enhancement of islet engraftment and achievement of long-term islet allograft survival by Toll-like receptor 4 blockade.

Giovannoni L, Muller YD, Lacotte S, Parnaud G, Borot S, Meier RP, Lavallard V, Bédat B, Toso C, Daubeuf B, Elson G, Shang L, Morel P, Kosco-Vilbois M, Bosco D, Berney T.

Transplantation. 2015 Jan;99(1):29-35. doi: 10.1097/TP.0000000000000468.

PMID:
25340601
19.

Selective antibody intervention of Toll-like receptor 4 activation through Fc γ receptor tethering.

Shang L, Daubeuf B, Triantafilou M, Olden R, Dépis F, Raby AC, Herren S, Dos Santos A, Malinge P, Dunn-Siegrist I, Benmkaddem S, Geinoz A, Magistrelli G, Rousseau F, Buatois V, Salgado-Pires S, Reith W, Monteiro R, Pugin J, Leger O, Ferlin W, Kosco-Vilbois M, Triantafilou K, Elson G.

J Biol Chem. 2014 May 30;289(22):15309-18. doi: 10.1074/jbc.M113.537936. Epub 2014 Apr 15.

20.

Anti-CD79 antibody induces B cell anergy that protects against autoimmunity.

Hardy IR, Anceriz N, Rousseau F, Seefeldt MB, Hatterer E, Irla M, Buatois V, Chatel LE, Getahun A, Fletcher A, Cons L, Pontini G, Hertzberg NA, Magistrelli G, Malinge P, Smith MJ, Reith W, Kosco-Vilbois MH, Ferlin WG, Cambier JC.

J Immunol. 2014 Feb 15;192(4):1641-50. doi: 10.4049/jimmunol.1302672. Epub 2014 Jan 17.

21.

Comparing CDRH3 diversity captured from secondary lymphoid organs for the generation of recombinant human antibodies.

Venet S, Kosco-Vilbois M, Fischer N.

MAbs. 2013 Sep-Oct;5(5):690-8. doi: 10.4161/mabs.25592. Epub 2013 Jul 2.

22.

Characterization of a surrogate murine antibody to model anti-human CD3 therapies.

Dépis F, Hatterer E, Ballet R, Daubeuf B, Cons L, Glatt S, Reith W, Kosco-Vilbois M, Dean Y.

MAbs. 2013 Jul-Aug;5(4):555-64. doi: 10.4161/mabs.24736. Epub 2013 Apr 18.

23.

Deep sequencing of phage display libraries to support antibody discovery.

Ravn U, Didelot G, Venet S, Ng KT, Gueneau F, Rousseau F, Calloud S, Kosco-Vilbois M, Fischer N.

Methods. 2013 Mar 15;60(1):99-110. doi: 10.1016/j.ymeth.2013.03.001. Epub 2013 Mar 14.

PMID:
23500657
24.

Germinal center B cells govern their own fate via antibody feedback.

Zhang Y, Meyer-Hermann M, George LA, Figge MT, Khan M, Goodall M, Young SP, Reynolds A, Falciani F, Waisman A, Notley CA, Ehrenstein MR, Kosco-Vilbois M, Toellner KM.

J Exp Med. 2013 Mar 11;210(3):457-64. doi: 10.1084/jem.20120150. Epub 2013 Feb 18.

25.

Combination therapies in the context of anti-CD3 antibodies for the treatment of autoimmune diseases.

Dean Y, Dépis F, Kosco-Vilbois M.

Swiss Med Wkly. 2012 Nov 28;142:w13711. doi: 10.4414/smw.2012.13711. eCollection 2012. Review.

26.

IL-17F co-expression improves cell growth characteristics and enhances recombinant protein production during CHO cell line engineering.

Contie M, Leger O, Fouque N, Poitevin Y, Kosco-Vilbois M, Mermod N, Elson G.

Biotechnol Bioeng. 2013 Apr;110(4):1153-63. doi: 10.1002/bit.24763. Epub 2012 Nov 23.

PMID:
23096947
27.

Transferring the characteristics of naturally occurring and biased antibody repertoires to human antibody libraries by trapping CDRH3 sequences.

Venet S, Ravn U, Buatois V, Gueneau F, Calloud S, Kosco-Vilbois M, Fischer N.

PLoS One. 2012;7(8):e43471. doi: 10.1371/journal.pone.0043471. Epub 2012 Aug 24.

28.

Long-term amelioration of established collagen-induced arthritis achieved with short-term therapy combining anti-CD3 and anti-tumor necrosis factor treatments.

Dépis F, Hatterer E, Lamacchia C, Waldburger JM, Gabay C, Reith W, Kosco-Vilbois M, Dean Y.

Arthritis Rheum. 2012 Oct;64(10):3189-98. doi: 10.1002/art.34497.

29.

Dual specificity of anti-CXCL10-CXCL9 antibodies is governed by structural mimicry.

Fagète S, Rousseau F, Magistrelli G, Gueneau F, Ravn U, Kosco-Vilbois MH, Fischer N.

J Biol Chem. 2012 Jan 6;287(2):1458-67. doi: 10.1074/jbc.M111.253658. Epub 2011 Oct 31.

30.

Robust recombinant FcRn production in mammalian cells enabling oriented immobilization for IgG binding studies.

Magistrelli G, Malinge P, Anceriz N, Desmurs M, Venet S, Calloud S, Daubeuf B, Kosco-Vilbois M, Fischer N.

J Immunol Methods. 2012 Jan 31;375(1-2):20-9. doi: 10.1016/j.jim.2011.09.002. Epub 2011 Sep 12.

PMID:
21939661
31.

Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis-associated tumorigenesis.

Fukata M, Shang L, Santaolalla R, Sotolongo J, Pastorini C, España C, Ungaro R, Harpaz N, Cooper HS, Elson G, Kosco-Vilbois M, Zaias J, Perez MT, Mayer L, Vamadevan AS, Lira SA, Abreu MT.

Inflamm Bowel Dis. 2011 Jul;17(7):1464-73. doi: 10.1002/ibd.21527. Epub 2010 Nov 15.

32.

CC chemokine CCL5 plays a central role impacting infarct size and post-infarction heart failure in mice.

Montecucco F, Braunersreuther V, Lenglet S, Delattre BM, Pelli G, Buatois V, Guilhot F, Galan K, Vuilleumier N, Ferlin W, Fischer N, Vallée JP, Kosco-Vilbois M, Mach F.

Eur Heart J. 2012 Aug;33(15):1964-74. doi: 10.1093/eurheartj/ehr127. Epub 2011 May 23.

PMID:
21606075
33.

Although IL-6 trans-signaling is sufficient to drive local immune responses, classical IL-6 signaling is obligate for the induction of T cell-mediated autoimmunity.

Lissilaa R, Buatois V, Magistrelli G, Williams AS, Jones GW, Herren S, Shang L, Malinge P, Guilhot F, Chatel L, Hatterer E, Jones SA, Kosco-Vilbois MH, Ferlin WG.

J Immunol. 2010 Nov 1;185(9):5512-21. doi: 10.4049/jimmunol.1002015. Epub 2010 Sep 24.

34.

By-passing in vitro screening--next generation sequencing technologies applied to antibody display and in silico candidate selection.

Ravn U, Gueneau F, Baerlocher L, Osteras M, Desmurs M, Malinge P, Magistrelli G, Farinelli L, Kosco-Vilbois MH, Fischer N.

Nucleic Acids Res. 2010 Nov;38(21):e193. doi: 10.1093/nar/gkq789. Epub 2010 Sep 15.

35.

Pan-CC chemokine neutralization restricts splenocyte egress and reduces inflammation in a model of arthritis.

Buatois V, Fagète S, Magistrelli G, Chatel L, Fischer N, Kosco-Vilbois MH, Ferlin WG.

J Immunol. 2010 Aug 15;185(4):2544-54. doi: 10.4049/jimmunol.1000182. Epub 2010 Jul 19.

36.

Toll-like receptor 4 signaling by follicular dendritic cells is pivotal for germinal center onset and affinity maturation.

Garin A, Meyer-Hermann M, Contie M, Figge MT, Buatois V, Gunzer M, Toellner KM, Elson G, Kosco-Vilbois MH.

Immunity. 2010 Jul 23;33(1):84-95. doi: 10.1016/j.immuni.2010.07.005.

37.

Rapid, simple and high yield production of recombinant proteins in mammalian cells using a versatile episomal system.

Magistrelli G, Malinge P, Lissilaa R, Fagète S, Guilhot F, Moine V, Buatois V, Delneste Y, Kellenberger S, Gueneau F, Ravn U, Kosco-Vilbois M, Fischer N.

Protein Expr Purif. 2010 Aug;72(2):209-16. doi: 10.1016/j.pep.2010.04.007. Epub 2010 Apr 24.

PMID:
20399863
38.

Specificity tuning of antibody fragments to neutralize two human chemokines with a single agent.

Fagète S, Ravn U, Gueneau F, Magistrelli G, Kosco-Vilbois MH, Fischer N.

MAbs. 2009 May-Jun;1(3):288-96.

39.

Neutralization of IFNgamma defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice.

Pachlopnik Schmid J, Ho CH, Chrétien F, Lefebvre JM, Pivert G, Kosco-Vilbois M, Ferlin W, Geissmann F, Fischer A, de Saint Basile G.

EMBO Mol Med. 2009 May;1(2):112-24. doi: 10.1002/emmm.200900009.

40.

The 16th International Conference on Lymphatic Tissues and Germinal Centers in Immune Responses.

Kosco-Vilbois M, Meyer-Hermann M.

Eur J Immunol. 2009 Sep;39(9):2311-2. doi: 10.1002/eji.200990298. No abstract available.

41.

A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis.

Ungaro R, Fukata M, Hsu D, Hernandez Y, Breglio K, Chen A, Xu R, Sotolongo J, Espana C, Zaias J, Elson G, Mayer L, Kosco-Vilbois M, Abreu MT.

Am J Physiol Gastrointest Liver Physiol. 2009 Jun;296(6):G1167-79. doi: 10.1152/ajpgi.90496.2008. Epub 2009 Apr 9.

42.

Deriving a germinal center lymphocyte migration model from two-photon data.

Figge MT, Garin A, Gunzer M, Kosco-Vilbois M, Toellner KM, Meyer-Hermann M.

J Exp Med. 2008 Dec 22;205(13):3019-29. doi: 10.1084/jem.20081160. Epub 2008 Dec 1.

43.

3D and 4D imaging of immune cells in vitro and in vivo.

Nitschke C, Garin A, Kosco-Vilbois M, Gunzer M.

Histochem Cell Biol. 2008 Dec;130(6):1053-62. doi: 10.1007/s00418-008-0520-x. Epub 2008 Oct 15. Review.

PMID:
18855003
44.

Follicular dendritic cells control engulfment of apoptotic bodies by secreting Mfge8.

Kranich J, Krautler NJ, Heinen E, Polymenidou M, Bridel C, Schildknecht A, Huber C, Kosco-Vilbois MH, Zinkernagel R, Miele G, Aguzzi A.

J Exp Med. 2008 Jun 9;205(6):1293-302. doi: 10.1084/jem.20071019. Epub 2008 May 19.

45.

Effect of Toll-like receptor 4 blockade on pulmonary inflammation caused by mechanical ventilation and bacterial endotoxin.

Smith LS, Kajikawa O, Elson G, Wick M, Mongovin S, Kosco-Vilbois M, Martin TR, Frevert CW.

Exp Lung Res. 2008 Jun;34(5):225-43. doi: 10.1080/01902140802022492.

PMID:
18465402
46.

TLR4/MD-2 monoclonal antibody therapy affords protection in experimental models of septic shock.

Daubeuf B, Mathison J, Spiller S, Hugues S, Herren S, Ferlin W, Kosco-Vilbois M, Wagner H, Kirschning CJ, Ulevitch R, Elson G.

J Immunol. 2007 Nov 1;179(9):6107-14.

47.

Pivotal involvement of Fcgamma receptor IIA in the neutralization of lipopolysaccharide signaling via a potent novel anti-TLR4 monoclonal antibody 15C1.

Dunn-Siegrist I, Leger O, Daubeuf B, Poitevin Y, Dépis F, Herren S, Kosco-Vilbois M, Dean Y, Pugin J, Elson G.

J Biol Chem. 2007 Nov 30;282(48):34817-27. Epub 2007 Oct 5.

48.

In vivo imaging of germinal centres reveals a dynamic open structure.

Schwickert TA, Lindquist RL, Shakhar G, Livshits G, Skokos D, Kosco-Vilbois MH, Dustin ML, Nussenzweig MC.

Nature. 2007 Mar 1;446(7131):83-7. Epub 2007 Jan 31.

PMID:
17268470
49.

Short-term treatment with anti-CD3 antibody reduces the development and progression of atherosclerosis in mice.

Steffens S, Burger F, Pelli G, Dean Y, Elson G, Kosco-Vilbois M, Chatenoud L, Mach F.

Circulation. 2006 Oct 31;114(18):1977-84. Epub 2006 Oct 16.

PMID:
17043169
50.

The generation of thymus-independent germinal centers depends on CD40 but not on CD154, the T cell-derived CD40-ligand.

Gaspal FM, McConnell FM, Kim MY, Gray D, Kosco-Vilbois MH, Raykundalia CR, Botto M, Lane PJ.

Eur J Immunol. 2006 Jul;36(7):1665-73.

Supplemental Content

Loading ...
Support Center